Research Findings

Purina Study: Lean Labradors Lived 1.8 Years Longer

Image
Purina Study: Lean Labradors Lived 1.8 Years Longer

St. Louis – October 13, 2026 -- Labrador Retrievers kept lean from puppyhood lived a median of 1.8 years longer than heavier matched littermates, according to findings from the 14-year Purina Life Span Study, which the Purina Institute is revisiting on the study's 25th anniversary.

Lean-fed dogs reached a median life span of 13.0 years versus 11.2 years for controls

The study followed 48 Labrador Retrievers from seven litters. Each pair of matched littermates received the same complete and balanced diet, but one dog was fed 25% less food than its sibling to maintain lean body condition. The sibling served as the control. The Purina Institute describes it as the first-ever canine lifelong dietary study.

The 1.8-year gap equals a 15% extension in median life span. Lean-fed dogs also stayed free of treatment for age-related chronic conditions for longer, reaching 12.0 years before treatment was required versus 9.9 years for control-fed dogs.

Resero Bio Urine Test Predicts Bladder Cancer Treatment Response

Image
Resero Bio Urine Test Predicts Bladder Cancer Treatment Response

San Carlos, Calif. – October 05, 2026 -- A non-invasive urine test can now predict whether bladder cancer patients will respond to immunotherapy before treatment even begins, according to a Stanford-led study published in Nature Medicine and announced by Resero Bio.

Study analyzed 683 urine samples to validate cell-free RNA platform

Researchers from Stanford Cancer Institute and the VA Palo Alto Health Care System used uRARE-seq, Resero Bio's proprietary targeted cfRNA sequencing method, to analyze 683 urine samples from bladder cancer patients and controls. The platform distinguished low-grade from high-grade tumors and non-muscle invasive from muscle-invasive disease, determinations that currently require tissue biopsy or surgical resection.

Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026

Image
Ro, Novo Unveil First Real-World Data on Wegovy Pill Switch at EASD2026

New York – September 30, 2026 -- Direct-to-patient healthcare company Ro presented the first real-world evidence on Novo Nordisk's oral Wegovy pill at the EASD2026 meeting in Milan on September 30, based on outcomes from patients on its platform who switched from an injectable GLP-1.

Ro's platform generates first clinical data on Wegovy pill switch patients

The short oral session study, co-authored by Ro clinical advisors Dr. Beverly Tchang and Dr. Louis Aronne, tracked patients with overweight or obesity who transitioned from an injectable GLP-1 and remained persistent with the Wegovy pill for three months on Ro's platform.

DCD Heart Transplants Expand in US Without Worse Outcomes, Study Finds

Image
DCD Heart Transplants Expand in US Without Worse Outcomes, Study Finds

Washington – September 15, 2026 -- Donation after circulatory death (DCD) heart transplantation expanded rapidly across the United States between 2019 and 2024 without any measurable decline in early clinical outcomes, according to research published in the September 2026 issue of the Journal of Cardiac Failure (JCF).

Registry data on 1,489 patients show no rise in graft failure or mortality

Investigators analyzed U.S. registry data covering 1,489 adult DCD heart transplant recipients, comparing the early adoption period of 2019-2021 with the national expansion period of 2022-2024. The analysis found no significant differences in one-year graft failure, mortality, need for renal replacement therapy, re-transplantation or hospital length of stay between the two periods. Outcomes remained consistent even among higher-risk recipients, as DCD transplantation spread to a growing number of transplant centers nationwide.